CDER "transformation initiative" based on "proactive strategic focus" -- Woodcock.
This article was originally published in The Tan Sheet
Executive Summary
CDER "TRANSFORMATION INITIATIVE" FOCUSING ON STRATEGIC APPROACH TO REGULATION, is needed, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, stated Sept. 30 at a Parenteral Drug Association/FDA joint conference in Washington, D.C. With FDA reform legislation put aside until next year, Woodcock underscored the need for internal FDA reform.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning